Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARC-520 in HBeAg positive chronic hepatitis B
NCT02452528Phase 2Terminated
- Sponsor
- Arrowhead Pharmaceuticals
- Start
- Aug 2015
- Primary completion
- Dec 2016
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Chronic Hepatitis B (CHB) comparing ARC-520 with Placebo (2 arms). Primary endpoint: Quantitative Hepatitis B Surface Antigen at Day 85. Started Aug 2015; status: terminated.
02
Drugs
ARC-520
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT02452528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452528.